quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·46d
PRRelease
Eledon Pharmaceuticals Inc. logo
NewcelX Ltd. logo

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

ELDN· Eledon Pharmaceuticals Inc.NCEL· NewcelX Ltd.
Health Care
Original source

Companies

  • ELDN
    Eledon Pharmaceuticals Inc.
    Health Care
  • NCEL
    NewcelX Ltd.
    Health Care

Recent analyst ratings

  • Jun 18ELDNUpdateH.C. Wainwright$9.00
  • Jan 28ELDNUpdateGuggenheim$9.00
  • May 13ELDNUpdateCantor Fitzgerald$15.00
  • Nov 24ELDNUpdateHC Wainwright & Co.$25.00

Related

  • SEC4d
    SEC Form 6-K filed by NewcelX Ltd.
  • PR4d
    NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
  • PR17d
    Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
  • SEC22d
    SEC Form 6-K filed by NewcelX Ltd.
  • PR23d
    NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Eledon Pharmaceuticals Inc.
  • PR35d
    Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
  • SEC35d
    SEC Form 10-K filed by Eledon Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022